سعر Meloxicam-El Nasr 5 mg/ml intramuscular injection (ampoules) 2026

Meloxicam 5 mg/ml intramuscular injection, 3 ampoules (El Nasr Pharmaceutical Chemicals, Egypt); the source name is marked "(n/a)", which suggests the product is not currently available.

• Children and adolescents under 18 years; third trimester of pregnancy.General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)
• Hypersensitivity to meloxicam or excipients, or asthma, nasal polyps, angioedema or urticaria after aspirin or other NSAIDs.General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)
• History of gastrointestinal bleeding or perforation related to NSAIDs, or active/recurrent peptic ulcer or haemorrhage; cerebrovascular or other bleeding disorders.General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)
• Severe hepatic impairment, non-dialysed severe renal failure and severe heart failure.General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)
• Coagulation disorders or concomitant anticoagulant treatment (intramuscular route).General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)

• Use the lowest effective dose for the shortest duration; NSAIDs carry risks of gastrointestinal bleeding, ulceration and perforation, cardiovascular and cerebrovascular thrombotic events, renal impairment and serious skin reactions; avoid combination with other NSAIDs.General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)

• Anticoagulants (e.g., warfarin), heparinIncreased bleeding risk; with the intramuscular formulation concomitant anticoagulation is contraindicated.Läkemedelsverket (Swedish Medical Products Agency)
• Other NSAIDs including aspirin at anti-inflammatory dosesNot recommended: increased risk of gastrointestinal ulceration and bleeding.Läkemedelsverket (Swedish Medical Products Agency)
• Lithium, methotrexateNSAIDs may raise lithium and methotrexate levels; monitor.Läkemedelsverket (Swedish Medical Products Agency)

• Should not be given in the first and second trimesters unless clearly necessary; contraindicated in the third trimester (risk of premature ductus arteriosus closure, renal dysfunction with oligohydramnios, prolonged bleeding and delayed labour).General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)
• NSAIDs pass into breast milk; use during breastfeeding requires weighing benefit against risk (the SmPC advises against use while breastfeeding unless the benefit justifies it).General active-ingredient information · Läkemedelsverket (Swedish Medical Products Agency)

• Meloxicam: Oxicam NSAID with anti-inflammatory, analgesic and antipyretic properties; inhibits prostaglandin biosynthesis.